Gubra A/S (GUBRA.CO)

DKK 374.0

(-2.6%)

Revenue Summary of Gubra A/S

Gubra A/S's latest annual revenue in 2023 was 205 Million DKK , up 2.82% from previous year.
Gubra A/S's latest quarterly revenue in 2024 Q1 was 60.31 Million DKK , up 16.9% from previous quarter.
Gubra A/S reported a annual revenue of 199.38 Million DKK in annual revenue 2022, down -21.91% from previous year.
Gubra A/S reported a annual revenue of 255.32 Million DKK in annual revenue 2021, up 48.19% from previous year.
Gubra A/S reported a quarterly revenue of 60.31 Million DKK for 2024 Q2, down 0.0% from previous quarter.
Gubra A/S reported a quarterly revenue of 50.9 Million DKK for 2023 Q1, up 0.12% from previous quarter.

Annual Revenue Chart of Gubra A/S (2023 - 2020)

Historical Annual Revenue of Gubra A/S (2023 - 2020)

Year	Revenue	Revenue Growth
2023	205 Million DKK	2.82%
2022	199.38 Million DKK	-21.91%
2021	255.32 Million DKK	48.19%
2020	172.3 Million DKK	0.0%

Year	Revenue	Revenue Growth
2024 Q1	60.31 Million DKK	16.9%
2024 Q2	60.31 Million DKK	0.0%
2023 Q1	50.9 Million DKK	0.12%
2023 FY	205 Million DKK	2.82%
2023 Q3	51.59 Million DKK	1.35%
2023 Q2	50.9 Million DKK	0.0%
2023 Q4	51.59 Million DKK	0.0%
2022 Q2	48.84 Million DKK	0.0%
2022 Q1	48.84 Million DKK	0.0%
2022 FY	199.38 Million DKK	-21.91%
2022 Q3	50.84 Million DKK	4.11%
2022 Q4	50.84 Million DKK	0.0%
2021 FY	255.32 Million DKK	48.19%
2020 FY	172.3 Million DKK	0.0%

Peer Revenue Comparison of Gubra A/S

Name	Revenue	Revenue Difference
ALK-Abelló A/S	4.82 Billion DKK	95.75%
Bavarian Nordic A/S	7.05 Billion DKK	97.095%
Genmab A/S	16.47 Billion DKK	98.756%
Novo Nordisk A/S	232.26 Billion DKK	99.912%
Orphazyme A/S	- DKK	-Infinity%
Pharma Equity Group A/S	- DKK	-Infinity%
Zealand Pharma A/S	342.78 Million DKK	40.195%